1,032
Views
8
CrossRef citations to date
0
Altmetric
Original Article

Long-term disease history, clinical symptoms, health status, and healthcare utilization in patients suffering from Lambert Eaton myasthenic syndrome: Results of a patient interview survey in Germany

, , , , , & show all
Pages 521-530 | Accepted 20 Jan 2012, Published online: 21 Feb 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Sabine Lindquist & Martin Stangel. (2014) 3,4-Diaminopyridine (amifampridine) for the treatment of Lambert–Eaton myasthenic syndrome. Expert Opinion on Orphan Drugs 2:3, pages 293-300.
Read now

Articles from other publishers (7)

Andreas Meisel, Jörn P. Sieb, Gwendal Le Masson, Ville Postila & Sabrina Sacconi. (2022) The European Lambert–Eaton Myasthenic Syndrome Registry: Long-Term Outcomes Following Symptomatic Treatment. Neurology and Therapy 11:3, pages 1071-1083.
Crossref
Na Zhang, Daojun Hong, Taohui Ouyang, Wei Meng, Jingwei Huang, Meihua Li & Tao Hong. (2021) 3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials. BMC Neurology 21:1.
Crossref
Alexander F. Lipka, Marion I. BoldinghErik W. van ZwetMarco W.J. SchreursJan B.M. KuksChantal M. TallaksenMaarten J. TitulaerJan J.G.M. Verschuuren. (2020) Long‐term follow‐up, quality of life, and survival of patients with Lambert‐Eaton myasthenic syndrome. Neurology 94:5.
Crossref
C. Michel Harper & Vanda A. Lennon. 2018. Myasthenia Gravis and Related Disorders. Myasthenia Gravis and Related Disorders 221 237 .
Simona Portaro, Teresa Brizzi, Stefano Sinicropi, Alberto Cacciola, Maria Cristina De Cola, Alessia Bramanti, Demetrio Milardi, Antonino Lupica, Placido Bramanti, Antonio Toscano & Carmelo Rodolico. (2017) Five years experience on 3,4-diaminopyridine phosphate in Lambert–Eaton syndrome. Medicine 96:38, pages e7839.
Crossref
Benedikt Schoser, Bruno Eymard, Joe Datt & Renato Mantegazza. (2017) Lambert–Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. Journal of Neurology 264:9, pages 1854-1863.
Crossref
Renato Mantegazza, Andreas Meisel, Joern P. Sieb, Gwendal Le Masson, Claude Desnuelle & Mirko Essing. (2015) The European LEMS Registry: Baseline Demographics and Treatment Approaches. Neurology and Therapy 4:2, pages 105-124.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.